We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App





Novel Coronavirus Breathalyzer Test Detects COVID-19 Non-Invasively in Seconds

By LabMedica International staff writers
Posted on 26 Aug 2020
A novel breathalyzer uses intelligent nanotechnology that is capable of rapidly detecting COVID-19 in exhaled breath and has “the potential to serve as a monitoring and epidemic control tool.”

A team of scientists from Technion - Israel Institute of Technology (Haifa, Israel) and Russell Berrie Nanotechnology Institute (Haifa, Israel), in collaboration with Chinese researchers, has devised a novel breath analyzer test to rapidly detect the disease caused by the novel coronavirus. More...
The testing device is an intelligent nanotechnology that can rapidly detect COVID-19 from specific volatile organic compounds (VOCs) in exhaled breath.

The efficacy of the COVID-19 breath analyzer testing device, which is comprised of a nanomaterial-based sensor array, was successfully validated in March by a preliminary case-control clinical study in China. It can detect disease-specific biomarkers in exhaled breath with 92% accuracy, 100% sensitivity, and 84% specificity. While a larger cohort study is still needed to validate the results, the researchers envision the test’s utility as a screening tool for airports, shopping centers, and other public places where the risk of community spread is high.

The pre-screening diagnostic system could offer a screening solution that can be performed at home or point-of-care facilities, greatly reducing unneeded confirmatory tests and reducing the burden on hospitals. Importantly, the artificial intelligence of the device can be modified and applied to any other infectious diseases. The researchers believe that this approach can serve as a platform for a rapidly available diagnostic tool that can be used in the case of a new disease outbreak.

Related Links:
Technion – Israel Institute of Technology
Russell Berrie Nanotechnology Institute



Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
Online QC Software
Acusera 24•7
New
Automated Urinalysis Solution
UN-9000
Hematology Consumables
Bioblood Devices
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Research team leader Professor Klaus Gerwert and study lead author Dr. Grischa Gerwert in a betaSENSE laboratory (Photo courtesy of Dennis Yenmez/Stadt Bochum)

Blood-Based Sensor Detects Early Signs of Alzheimer’s and Parkinson’s

Alzheimer’s disease and Parkinson’s disease are increasing as populations age, yet diagnosis remains largely symptom-driven and often occurs after irreversible brain damage has begun. Earlier detection,... Read more

Pathology

view channel
Image: Immune-related signals in routine bone marrow biopsy slides could help predict multiple myeloma outcomes and support more personalized treatment strategies (image credit: Shutterstock)

AI Tool Extracts Immune Signals from Biopsy to Inform Myeloma Therapy

Multiple myeloma is a bone marrow malignancy in which patients can respond very differently to the same treatments, making initial therapy decisions difficult. Clinicians must choose among options such... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.